Study to Evaluate the Efficacy of Blue Fenugreek Kale Extract (BFKE) on Skin

NCT ID: NCT04544982

Last Updated: 2021-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-01

Study Completion Date

2021-03-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants will be supplemented BFKE for a period of 8-weeks to improve skin health. The objective of the study is to evaluate the 'Transepidermal Water Loss (TEWL)' that characterizes the skin barrier function of stratum corneum. Additional parameters include, evaluation of skin moisture content, wrinkling, elasticity, sagging, radiance and also on inflammatory biomarkers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blue fenugreek kale extract

One capsule to be taken orally before breakfast and one capsule after lunch, with water.

Group Type ACTIVE_COMPARATOR

Blue fenugreek kale extract

Intervention Type OTHER

One capsule to be taken orally before breakfast and one capsule after lunch, with water.

Placebo

One capsule to be taken orally before breakfast and one capsule after lunch, with water.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

One capsule to be taken orally before breakfast and one capsule after lunch, with water.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blue fenugreek kale extract

One capsule to be taken orally before breakfast and one capsule after lunch, with water.

Intervention Type OTHER

Placebo

One capsule to be taken orally before breakfast and one capsule after lunch, with water.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, adult female participants aged ≥ 30 and ≤ 55 years.
* Participants with signs of poor skin barrier as determined by Trans-epidermal water loss ≥ 15 g/m2/h on forehead.
* Participants with skin type II to IV as per Fitzpatrick skin type calculator.
* Participants with skin type II and III as per Glogau's classification of photoageing skin.
* Participants must have Body Mass Index (BMI) ≥ 18.5 ≤ 29.9 kg/m2.
* Participants with moderate signs of Melasma as assessed by the investigators.
* Participants ready to abstain from any cosmetic or drug-based cream, ointment, lotion and other products apart from the ones allowed during study period.
* Participants ready to rinse their face only with water and to refrain from using soap, facewash, make-up etc. or any other cosmetic care related products 12 hrs. prior to any assessment visit.

Exclusion Criteria

* Unwilling to forgo any aesthetic or dermatological treatments or procedures during the study period.
* Participants with visible scarring on face.
* Participants having any form of skin disorder on the Nasolabial fold.
* Water consumption history of ≤ 500 ml and ≥ 3000 ml per day.
* Smoking or using any tobacco products.
* Participants presently undergoing or had undergone treatment for softening or reducing wrinkles in the last 3 months.
* Having a history of chronic skin allergies.
* History of heavy caffeine usage ≥ 4 cups in a day.
* Binge drinkers as defined by consumption of 4 or more alcohol containing beverages within 2 hours.
* Presence of unstable, acutely symptomatic, or life-limiting illness.
* Participants taking any vitamins and other related supplements.
* Menopausal and peri-menopausal females.
* Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
* Females who have had participated in a study of an investigational product 90 days prior to the screening.
Minimum Eligible Age

30 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vedic Lifesciences Pvt. Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Skin cure and care clinic

Thāne, Maharashtra, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MGB/191101/BFKE/SKNM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.